NEW YORK, Jan 12, 2026, 12:58 PM EST — Regular session
- BillionToOne shares jumped roughly 7% midday following the release of its inaugural full-year 2026 revenue forecast
- The diagnostics firm reaffirmed its 2025 revenue forecast and now projects positive GAAP operating income by 2026
- Investors want clearer insight from the company’s J.P. Morgan Healthcare Conference materials
BillionToOne shares climbed roughly 7% to $92.20 during Monday’s midday session, following the company’s release of its 2026 forecast.
The guidance is crucial since the company remains in its early days as a public stock, with investors eager to gauge its growth pace while maintaining profitability. The target is now clear for 2026.
The timing coincides with the J.P. Morgan Healthcare Conference, where healthcare firms vie for attention and investment. For a fresh public company, this can turn a standard forecast into a trigger for immediate trading action.
BillionToOne projects total revenue between $415 million and $430 million for 2026, while reaffirming its full-year 2025 revenue forecast of $293 million to $299 million. The company also anticipates turning a positive GAAP operating income in 2026, reflecting profit under U.S. accounting standards. CEO Dr. Oguzhan Atay highlighted the potential to “scale” the platform and maintain a “durable” growth trajectory. Securities and Exchange Commission
The high end of that revenue forecast exceeds the $393.61 million average 2026 estimate from eight analysts tracked by Nasdaq.com, a variance traders typically target during a stock’s initial quarters as a public company. Nasdaq
BillionToOne is working on non-invasive blood tests for prenatal screening and oncology, a field known for rapid growth but heavy oversight from doctors, payers, and regulators. Its prenatal product goes by Unity, while the Northstar line focuses on cancer diagnosis. Reuters
The company set its IPO price at $60 per share back in November, bringing in roughly $273 million, Reuters reported. Reuters
Analysts say the real upside depends on execution beyond prenatal screening, particularly in oncology. In a Dec. 1 initiation note, William Blair’s Andrew Brackmann described BillionToOne as “a commercial-stage, rapidly growing, profitable lab company,” highlighting a planned launch of a minimal residual disease (MRD) test in 2026 as a key milestone. (MRD tests detect tiny traces of cancer post-treatment.) William Blair
The risk is clear: guidance represents a target, not a guarantee. Any hiccup in test volumes, reimbursement rates, or the speed of oncology adoption could dent revenue. Even with “positive” GAAP operating income, there’s still significant room for misses that would look bad in quarterly results.
Investors are looking for more details on the forecast in BillionToOne’s J.P. Morgan Healthcare Conference materials. The company said in a filing it plans to upload the presentation to its investor website on Monday. Securities and Exchange Commission
